Inside USP: Revising USP General Notices - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inside USP: Revising USP General Notices
USP is revising key documents to make them easier to use.

Pharmaceutical Technology

Official versus authorized text. The proposed revision to the General Notices attempts to clarify the distinction between official and authorized text. In this proposal, official text appears in USP, NF, FCC, or SALMOUS. All other text would be authorized.

Currently, all General Chapters are official by virtue of their inclusion in USP–NF and are recognized in law as official compendia of the United States. USP–NF distinguishes between enforceable and informational General Chapters by means of chapter numbers: Chapters numbered below 1000 are intended to be enforceable by FDA, but chapters numbered above 1000 are intended by USP to be informational only.

USP is aware that this numerical distinction is not entirely adequate and causes confusion within industry and regulatory authorities. Inclusion of General Information Chapters in the official compendium may at times cause them to be given greater regulatory status than USP intended. In addition, the distinction is imperfect: some chapters with numbers above 1000 may be referenced in a monograph, which makes the General Chapters mandatory for those monographs.

The current draft revision of the General Notices clarifies the text that is official, and therefore enforceable, in a new way:
  • USP, NF, FCC, and SALMOUS monographs all would be official
  • The General Notices would remain official
  • General Chapters and FCC General Tests and Assays that are included in USP, NF, or FCC would be official and therefore enforceable, whether the chapter number is above or below 1000. These would include every General Chapter that is referenced in an official USP, NF, FCC, or SALMOUS monograph. Other General Chapters also would be included, as determined by the relevant USP Expert Committees. General Chapters that remain official might include those that provide information that is necessary to perform compendial procedures and those that are anticipated to be referenced in a monograph in the near future.
  • Some information that currently is published in USP–NF would be considered authorized text only and would no longer be official. This text is expected to move to a new volume (the Companion Volume) that would not be called USP–NF in order to clarify to regulatory authorities that these materials are not intended to be enforceable. Some USP General Chapters would move to the Companion Volume. These chapters would retain their chapter numbers. The Reference Tables section of USP, including the Description and Solubility Table, also would move to the Companion Volume as authorized text.
  • Pending Standards would remain authorized text. Manufacturers are not permitted to claim conformance to a Pending Standards monograph.
  • Other text, such as Information monographs, would remain authorized and would remain outside of USP–NF and FCC.

The General Notices revision process

An overview of the General Notices revision process is posted on USP's website at The page contains a link to the 21-page proposed revisions. The revisions page will remain live for a first round of comments until August 31, 2007, and constituents are invited to submit comments via email to
or to:
Executive Secretariat
Attn: General Notices
US Pharmacopeia
12601 Twinbrook Pkwy
Rockville MD 20852-1790


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here